Biocytogen Announces Grand Opening of Waltham, MA Facility

State-of-the-Art Facility Signifies Growth of Business in North America and Europe

WALTHAM, Mass. & BEIJING--(BUSINESS WIRE)-- Biocytogen Pharmaceuticals (HKEX: 02315; “Biocytogen”), a biotechnology company focused on the generation and validation of novel antibody-based therapeutics and specialized animal models for partners worldwide, today announces the grand opening of a new 37,000 sqft. facility in Waltham, MA for its US-based subsidiary, Biocytogen Boston Corporation (hereafter “Biocytogen Boston”). The state-of-the-art facility, conveniently located at 300 Third Avenue, will triple Biocytogen Boston’s workspace, and includes a climate-controlled 4,000 cage vivarium, cell culture and procedure suites, and an open design concept to facilitate collaboration among employees and visiting clients.

The new location will focus on preclinical contract research services and the distribution of specialized animal model products (collectively termed “BioMice”) to support the increasing demand for projects from clients in North America and Europe. As one of the leading providers of humanized animal models worldwide, Biocytogen offers more than 500 strains of these specialized mice for generating and testing novel antibody and cell-based therapeutics in vivo. Furthermore, Biocytogen’s flagship RenMab™ model and its second-generation RenMice^Ⓡ-based platforms are powerful tools used to discover new fully human antibodies that can be developed into multiple therapeutic modalities, including naked antibodies, bi/trispecific antibodies, bispecific ADC, CAR-T, and CAR-NK. In addition to the research and technology teams, the company’s new location will support Biocytogen’s expanding business development initiatives, including establishing new client partnerships and out-licensing new products.

Dr. Qingcong Lin, Senior Vice President of Biocytogen and CEO of Biocytogen Boston, said, “This move signifies an exciting new chapter for Biocytogen. Our team’s dedication to providing high-quality preclinical models and services has led to the exponential growth of our business over the past 5 years, across both North America and Europe. We’re extremely excited for the opportunity to continue our commitment to experimental excellence our clients depend on and come to expect, but on a larger scale. We look forward to welcoming current and prospective clients/partners to this state-of-the-art facility to accelerate further collaboration.”

Dr. Yuelei Shen, Founder, President and CEO of Biocytogen, said, “Since Biocytogen’s inception in Worcester, MA, greater Boston has been a key area for distribution of Biocytogen’s animal model products. Over the past 14 years, our company’s portfolio has evolved to include pharmacology evaluation services, and most recently, antibody discovery services and antibody asset research and development. I expect that this new facility will be a key catalyst for our business to bring in new partners and clients looking to succeed in their antibody drug discovery efforts.”

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™ /RenLite^®/RenNano^® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice^® HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice^® licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. The company’s sub-brand, BioMice, encompasses the generation and distribution of animal model products and preclinical contract research services for clients around the globe. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit www.biocytogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230816833456/en/